Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
COSMOS Pharmaceutical Corporation ( (JP:3349) ) has issued an update.
Cosmos Pharmaceutical reported consolidated net sales of ¥810.38 billion for the nine months ended Feb. 28, 2026, up 7.7% year on year, while operating profit rose 1.2% to ¥32.02 billion and profit attributable to owners increased 1.8% to ¥22.75 billion, indicating modest profit growth despite strong top-line expansion. The company’s financial position remained solid with total assets of ¥546.75 billion, an equity ratio of 50.2%, and it maintained guidance for full-year sales of ¥1.057 trillion and profit stability, alongside a planned annual dividend increase to ¥75 per share, signaling confidence in its earnings capacity and shareholder returns.
The most recent analyst rating on (JP:3349) stock is a Buy with a Yen9500.00 price target. To see the full list of analyst forecasts on COSMOS Pharmaceutical Corporation stock, see the JP:3349 Stock Forecast page.
More about COSMOS Pharmaceutical Corporation
Cosmos Pharmaceutical Corporation is a Japan-based company listed on the Tokyo Stock Exchange that operates in the pharmaceutical and drugstore retail sector. The company focuses on selling pharmaceuticals and related products through its store network, targeting consumers across Japan and aiming for steady, long-term growth in sales and earnings.
Average Trading Volume: 550,570
Technical Sentiment Signal: Sell
Current Market Cap: Yen511B
Find detailed analytics on 3349 stock on TipRanks’ Stock Analysis page.